The resolvin D1 analogue controls maturation of dendritic cells and suppresses alloimmunity in corneal transplantation

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 9, 2014, Pages 5944-5951

  Hua, Jing ^a   Jin, Yiping ^a   Chen, Yihe ^a   Inomata, Takenori ^a   Lee, HyunSoo ^a   Chauhan, Sunil K ^a   Petasis, Nicos A ^b   Serhan, Charles N ^c   Dana, Reza ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Dendritic Cell; Resolvin; Transplant Rejection

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 12P70; LIPOXIN A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; REGULATOR PROTEIN; RESOLVIN D1A; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; DOCOSAHEXAENOIC ACID; RESOLVIN; RESOLVIN D1;

ALLOIMMUNITY; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MATURATION; CORNEA TRANSPLANTATION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GRAFT REJECTION; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; T LYMPHOCYTE; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW CELL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECT; GRAFT SURVIVAL; IMMUNOLOGY; METHODOLOGY;

DENDRITIC CELL; RESOLVIN; TRANSPLANT REJECTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; CORNEAL TRANSPLANTATION; DENDRITIC CELLS; DOCOSAHEXAENOIC ACIDS; GRAFT REJECTION; GRAFT SURVIVAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84908097560     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14356     Document Type: Article

References (63)

1. Serhan CN. Mediator lipidomics. Prostaglandins Other Lipid Mediat. 2005;77:4-14.
2. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101-137.
3. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196:1025-1037.
4. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000;192:1197-1204.
5. Dalli J, Serhan CN. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood. 2012;120:e60-e72.
6. Ramon S, Gao F, Serhan CN, Phipps RP. Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells. J Immunol. 2012;189:1036-1042.
7. Odusanwo O, Chinthamani S, McCall A, Duffey ME, Baker OJ. Resolvin D1 prevents TNF-alpha-mediated disruption of salivary epithelial formation. Am J Physiol Cell Physiol. 2012;302:C1331-C1345.
8. Claria J, Dalli J, Yacoubian S, Gao F, Serhan CN. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol. 2012;189:2597-2605.
9. Dartt DA, Hodges RR, Li D, Shatos MA, Lashkari K, Serhan CN. Conjunctival goblet cell secretion stimulated by leukotrienes is reduced by resolvins D1 and E1 to promote resolution of inflammation. J Immunol. 2011;186:4455-4466.
10. Duffield JS, Hong S, Vaidya VS, et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol. 2006; 177:5902-5911.
11. Xu ZZ, Zhang L, Liu T, et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med. 2010;16:592-597.
12. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nature Immunol. 2001;2:612-619.
13. Jin Y, Arita M, Zhang Q, et al. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci. 2009;50:4743-4752.
14. Ganea D, Kocieda V, Kong W, Yen JH. Modulation of dendritic cell function by PGE2 and DHA: a framework for understanding the role of dendritic cells in neuroinflammation. Clin Lipidol. 2011;6:277-291.
15. Chiang N, Fredman G, Backhed F, et al. Infection regulates proresolving mediators that lower antibiotic requirements. Nature. 2012;484:524-528.
16. Krishnamoorthy S, Recchiuti A, Chiang N, et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010;107:1660-1665.
17. Norling LV, Dalli J, Flower RJ, Serhan CN, Perretti M. Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol. 2012;32:1970-1978.
18. Rogerio AP, Haworth O, Croze R, et al. Resolvin D1 and aspirintriggered resolvin D1 promote resolution of allergic airways responses. J Immunol. 2012;189:1983-1991.
19. Arita M, Bianchini F, Aliberti J, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005;201: 713-722.
20. Vassiliou EK, Kesler OM, Tadros JH, Ganea D. Bone marrowderived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4þ T cells. J Immunol. 2008;181:4534-4544.
21. Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G, Serhan CN. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012;180:2018-2027.
22. Liu Y, Chen K, Wang C, et al. Cell surface receptor FPR2 promotes antitumor host defense by limiting M2 polarization of macrophages. Cancer Res. 2013;73:550-560.
23. Gao JL, Guillabert A, Hu J, et al. F2L, a peptide derived from heme-binding protein, chemoattracts mouse neutrophils by specifically activating Fpr2, the low-affinity N-formylpeptide receptor. J Immunol. 2007;178:1450-1456.
24. Chen K, Le Y, Liu Y, et al. A critical role for the g proteincoupled receptor mFPR2 in airway inflammation and immune responses. J Immunol. 2010;184:3331-3335.
25. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation— friend or foe? Immunity. 2001;14:357-368.
26. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7: 610-621.
27. Steinman RM, Gutchinov B, Witmer MD, Nussenzweig MC. Dendritic cells are the principal stimulators of the primary mixed leukocyte reaction in mice. J Exp Med. 1983;157:613-627.
28. Yamagami S, Dana MR. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci. 2001;42:1293-1298.
29. Yamagami S, Dana MR, Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to highrisk corneal transplantation. Cornea. 2002;21:405-409.
30. He YG, Ross J, Niederkorn JY. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti- CD4 monoclonal antibody. Invest Ophthalmol Vis Sci. 1991; 32:2723-2728.
31. Huq S, Liu Y, Benichou G, Dana MR. Relevance of the direct pathway of sensitization in corneal transplantation is dictated by the graft bed microenvironment. J Immunol. 2004;173: 4464-4469.
32. Yamagami S, Kawashima H, Endo H, et al. Cytokine profiles of aqueous humor and graft in orthotopic mouse corneal transplantation. Transplantation. 1998;66:1504-1510.
33. Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res. 2007;32:1005-1016.
34. Inaba K, Inaba M, Deguchi M, et al. Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci U S A. 1993;90:3038-3042.
35. Kasuga K, Yang R, Porter TF, et al. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol. 2008;181:8677-8687.
36. Sun YP, Oh SF, Uddin J, et al. Resolvin D1 and its aspirintriggered 17R epimer. Stereochemical assignments, antiinflammatory properties, and enzymatic inactivation. J Biol Chem. 2007;282:9323-9334.
37. Jin Y, Shen L, Chong EM, et al. The chemokine receptor CCR7 mediates corneal antigen-presenting cell trafficking. Mol Vis. 2007;13:626-634.
38. Sano Y, Ksander BR, Streilein JW. Murine orthotopic corneal transplantation in high-risk eyes. Rejection is dictated primarily by weak rather than strong alloantigens. Invest Ophthalmol Vis Sci. 1997;38:1130-1138.
39. Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana MR. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class IIpositive dendritic cells derived from MHC class II-negative grafts. J Exp Med. 2002;195:259-268.
40. Kasuga K, Yang R, Porter TF, et al. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol. 2008;181:8677-8687.
41. Sun YP, Oh SF, Uddin J, et al. Resolvin D1 and its aspirintriggered 17R epimer. Stereochemical assignments, antiinflammatory properties, and enzymatic inactivation. J Biol Chem. 2007;282:9323-9334.
42. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev. 2011;111:5922-5943.
43. Jin Y, Chauhan SK, El Annan J, Sage PT, Sharpe AH, Dana R. A novel function for programmed death ligand-1 regulation of angiogenesis. Am J Pathol. 2011;178:1922-1929.
44. Chen L, Hamrah P, Cursiefen C, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med. 2004;10:813-815.
45. Boisgerault F, Liu Y, Anosova N, Ehrlich E, Dana MR, Benichou G. Role of CD4þand CD8þT cells in allorecognition: lessons from corneal transplantation. J Immunol. 2001;167:1891-1899.
46. Niederkorn JY. Corneal transplantation and immune privilege. Int Rev Immunol. 2013;32:57-67.
47. Serhan CN, Krishnamoorthy S, Recchiuti A, Chiang N. Novel anti-inflammatory-pro-resolving mediators and their receptors. Curr Top Med Chem. 2011;11:629-647.
48. Uddin M, Levy BD. Resolvins: natural agonists for resolution of pulmonary inflammation. Prog Lipid Res. 2011;50:75-88.
49. Cooray SN, Gobbetti T, Montero-Melendez T, et al. Ligandspecific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci U S A. 2013;110:18232-18237.
50. Yang D, Chen Q, Le Y, Wang JM, Oppenheim JJ. Differential regulation of formyl peptide receptor-like 1 expression during the differentiation of monocytes to dendritic cells and macrophages. J Immunol. 2001;166:4092-4098.
51. Kong W, Yen JH, Vassiliou E, Adhikary S, Toscano MG, Ganea D. Docosahexaenoic acid prevents dendritic cell maturation and in vitro and in vivo expression of the IL-12 cytokine family. Lipids Heath Dis. 2010;9:12.
52. Zeyda M, Saemann MD, Stuhlmeier KM, et al. Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-kappaB activation. J Biol Chem. 2005; 280:14293-14301.
53. Qian Y, Boisgerault F, Benichou G, Dana MR. Blockade of CD40-CD154 costimulatory pathway promotes survival of allogeneic corneal transplants. Invest Ophthalmol Vis Sci. 2001;42:987-994.
54. Ganea D, Kocieda V, Kong W, Yen JH. Modulation of dendritic cell function by PGE2 and DHA: a framework for understanding the role of dendritic cells in neuroinflammation. Clin Lipidol. 2011;6:277-291.
55. Zapata-Gonzalez F, Rueda F, Petriz J, et al. Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR(gamma):RXR heterodimers: comparison with other polyunsaturated fatty acids. J Leukoc Biol. 2008;84:1172-1182.
56. Wang H, Hao Q, Li QR, et al. Omega-3 polyunsaturated fatty acids affect lipopolysaccharide-induced maturation of dendritic cells through mitogen-activated protein kinases p 38. Nutrition. 2007;23:474-482.
57. Zeyda M, Saemann MD, Stuhlmeier KM, et al. Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-kappaB activation. J Biol Chem. 2005; 280:14293-14301.
58. Kong W, Yen JH, Ganea D. Docosahexaenoic acid prevents dendritic cell maturation, inhibits antigen-specific Th1/Th17 differentiation and suppresses experimental autoimmune encephalomyelitis. Brain Behav Immun. 2011;25:872-882.
59. Hargrave SL, Hay C, Mellon J, Mayhew E, Niederkorn JY. Fate of MHC-matched corneal allografts in Th1-deficient hosts. Invest Ophthalmol Vis Sci. 2004;45:1188-1193.
60. Hamrah P, Liu Y, Zhang Q, Dana MR. The corneal stroma is endowed with a significant number of resident dendritic cells. Invest Ophthalmol Vis Sci. 2003;44:581-589.
61. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A. 2006;103: 11405-11410.
62. Tan Y, Cruz-Guilloty F, Medina-Mendez CA, et al. Immunological disruption of antiangiogenic signals by recruited allospecific T cells leads to corneal allograft rejection. J Immunol. 2012;188:5962-5969.
63. Dana MR. Angiogenesis and lymphangiogenesis-implications for corneal immunity. Semin Ophthalmol. 2006;21:19-22.